Crystal structures of the endoplasmic reticulum aminopeptidase-1 (ERAP1) reveal the molecular basis for N-terminal peptide trimming. 2011

Grazyna Kochan, and Tobias Krojer, and David Harvey, and Roman Fischer, and Liye Chen, and Melanie Vollmar, and Frank von Delft, and Kathryn L Kavanagh, and Matthew A Brown, and Paul Bowness, and Paul Wordsworth, and Benedikt M Kessler, and Udo Oppermann
Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Headington OX3 7DQ, United Kingdom.

Endoplasmatic reticulum aminopeptidase 1 (ERAP1) is a multifunctional enzyme involved in trimming of peptides to an optimal length for presentation by major histocompatibility complex (MHC) class I molecules. Polymorphisms in ERAP1 have been associated with chronic inflammatory diseases, including ankylosing spondylitis (AS) and psoriasis, and subsequent in vitro enzyme studies suggest distinct catalytic properties of ERAP1 variants. To understand structure-activity relationships of this enzyme we determined crystal structures in open and closed states of human ERAP1, which provide the first snapshots along a catalytic path. ERAP1 is a zinc-metallopeptidase with typical H-E-X-X-H-(X)(18)-E zinc binding and G-A-M-E-N motifs characteristic for members of the gluzincin protease family. The structures reveal extensive domain movements, including an active site closure as well as three different open conformations, thus providing insights into the catalytic cycle. A K(528)R mutant strongly associated with AS in GWAS studies shows significantly altered peptide processing characteristics, which are possibly related to impaired interdomain interactions.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011499 Protein Processing, Post-Translational Any of various enzymatically catalyzed post-translational modifications of PEPTIDES or PROTEINS in the cell of origin. These modifications include carboxylation; HYDROXYLATION; ACETYLATION; PHOSPHORYLATION; METHYLATION; GLYCOSYLATION; ubiquitination; oxidation; proteolysis; and crosslinking and result in changes in molecular weight and electrophoretic motility. Amino Acid Modification, Post-Translational,Post-Translational Modification,Post-Translational Protein Modification,Posttranslational Modification,Protein Modification, Post-Translational,Amino Acid Modification, Posttranslational,Post-Translational Amino Acid Modification,Post-Translational Modifications,Post-Translational Protein Processing,Posttranslational Amino Acid Modification,Posttranslational Modifications,Posttranslational Protein Processing,Protein Processing, Post Translational,Protein Processing, Posttranslational,Amino Acid Modification, Post Translational,Modification, Post-Translational,Modification, Post-Translational Protein,Modification, Posttranslational,Modifications, Post-Translational,Modifications, Post-Translational Protein,Modifications, Posttranslational,Post Translational Amino Acid Modification,Post Translational Modification,Post Translational Modifications,Post Translational Protein Modification,Post Translational Protein Processing,Post-Translational Protein Modifications,Processing, Post-Translational Protein,Processing, Posttranslational Protein,Protein Modification, Post Translational,Protein Modifications, Post-Translational
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000626 Aminopeptidases A subclass of EXOPEPTIDASES that act on the free N terminus end of a polypeptide liberating a single amino acid residue. EC 3.4.11. Aminopeptidase
D013167 Spondylitis, Ankylosing A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions. Ankylosing Spondylitis,Bechterew Disease,Marie-Struempell Disease,Rheumatoid Spondylitis,Spondylarthritis Ankylopoietica,Ankylosing Spondylarthritis,Ankylosing Spondyloarthritis,Bechterew's Disease,Spondylitis Ankylopoietica,Spondyloarthritis Ankylopoietica,Ankylosing Spondylarthritides,Ankylosing Spondyloarthritides,Bechterews Disease,Marie Struempell Disease,Spondylarthritides, Ankylosing,Spondylarthritis, Ankylosing,Spondylitis, Rheumatoid,Spondyloarthritides, Ankylosing,Spondyloarthritis, Ankylosing
D015778 Minor Histocompatibility Antigens Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In the mouse they are coded by more than 500 genes at up to 30 minor histocompatibility loci. The most well-known minor histocompatibility antigen in mammals is the H-Y antigen. Histocompatibility Antigens, Minor,Minor Histocompatibility Antigen,Minor Histocompatibility Peptide,Minor Histocompatibility Peptides,Antigen, Minor Histocompatibility,Histocompatibility Antigen, Minor,Histocompatibility Peptide, Minor,Histocompatibility Peptides, Minor,Peptide, Minor Histocompatibility
D015796 HLA-B27 Antigen A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*27 allele family. HLA Class I Histocompatibility Antigen, B-27 alpha Chain,HLA-B27,Antigen, HLA-B27,HLA B27 Antigen,HLA Class I Histocompatibility Antigen, B 27 alpha Chain

Related Publications

Grazyna Kochan, and Tobias Krojer, and David Harvey, and Roman Fischer, and Liye Chen, and Melanie Vollmar, and Frank von Delft, and Kathryn L Kavanagh, and Matthew A Brown, and Paul Bowness, and Paul Wordsworth, and Benedikt M Kessler, and Udo Oppermann
July 2005, Nature immunology,
Grazyna Kochan, and Tobias Krojer, and David Harvey, and Roman Fischer, and Liye Chen, and Melanie Vollmar, and Frank von Delft, and Kathryn L Kavanagh, and Matthew A Brown, and Paul Bowness, and Paul Wordsworth, and Benedikt M Kessler, and Udo Oppermann
May 2011, Nature structural & molecular biology,
Grazyna Kochan, and Tobias Krojer, and David Harvey, and Roman Fischer, and Liye Chen, and Melanie Vollmar, and Frank von Delft, and Kathryn L Kavanagh, and Matthew A Brown, and Paul Bowness, and Paul Wordsworth, and Benedikt M Kessler, and Udo Oppermann
January 2011, Scientific reports,
Grazyna Kochan, and Tobias Krojer, and David Harvey, and Roman Fischer, and Liye Chen, and Melanie Vollmar, and Frank von Delft, and Kathryn L Kavanagh, and Matthew A Brown, and Paul Bowness, and Paul Wordsworth, and Benedikt M Kessler, and Udo Oppermann
January 2020, Biological & pharmaceutical bulletin,
Grazyna Kochan, and Tobias Krojer, and David Harvey, and Roman Fischer, and Liye Chen, and Melanie Vollmar, and Frank von Delft, and Kathryn L Kavanagh, and Matthew A Brown, and Paul Bowness, and Paul Wordsworth, and Benedikt M Kessler, and Udo Oppermann
December 2019, Proceedings of the National Academy of Sciences of the United States of America,
Grazyna Kochan, and Tobias Krojer, and David Harvey, and Roman Fischer, and Liye Chen, and Melanie Vollmar, and Frank von Delft, and Kathryn L Kavanagh, and Matthew A Brown, and Paul Bowness, and Paul Wordsworth, and Benedikt M Kessler, and Udo Oppermann
August 2019, Cancer immunology, immunotherapy : CII,
Grazyna Kochan, and Tobias Krojer, and David Harvey, and Roman Fischer, and Liye Chen, and Melanie Vollmar, and Frank von Delft, and Kathryn L Kavanagh, and Matthew A Brown, and Paul Bowness, and Paul Wordsworth, and Benedikt M Kessler, and Udo Oppermann
April 2020, Gene,
Grazyna Kochan, and Tobias Krojer, and David Harvey, and Roman Fischer, and Liye Chen, and Melanie Vollmar, and Frank von Delft, and Kathryn L Kavanagh, and Matthew A Brown, and Paul Bowness, and Paul Wordsworth, and Benedikt M Kessler, and Udo Oppermann
January 2013, Nature communications,
Grazyna Kochan, and Tobias Krojer, and David Harvey, and Roman Fischer, and Liye Chen, and Melanie Vollmar, and Frank von Delft, and Kathryn L Kavanagh, and Matthew A Brown, and Paul Bowness, and Paul Wordsworth, and Benedikt M Kessler, and Udo Oppermann
May 2018, The Journal of biological chemistry,
Grazyna Kochan, and Tobias Krojer, and David Harvey, and Roman Fischer, and Liye Chen, and Melanie Vollmar, and Frank von Delft, and Kathryn L Kavanagh, and Matthew A Brown, and Paul Bowness, and Paul Wordsworth, and Benedikt M Kessler, and Udo Oppermann
October 2015, The Journal of biological chemistry,
Copied contents to your clipboard!